HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke

Launched by ZI-XIAO LI · Mar 12, 2024

Keywords

ClinConnect Summary

The "HOPE from the Cerebellum" clinical trial is looking into a treatment called repetitive transcranial magnetic stimulation (rTMS) to help improve thinking and memory skills in people who have had a stroke. Specifically, the trial focuses on individuals who have experienced an ischemic stroke, where a blood vessel in the brain is blocked, leading to cognitive issues. The treatment involves applying rTMS to a part of the brain called the cerebellum, which is located on the opposite side of the brain from where the stroke occurred. Participants will receive this treatment once a day for five days.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have had a stroke within the last two weeks that resulted in cognitive impairment, as measured by a specific test. However, individuals with certain conditions, such as bleeding in the brain or a history of seizures, cannot participate. This trial is not yet recruiting participants, but it aims to provide valuable insights into how rTMS can aid recovery after a stroke, potentially helping many individuals regain their cognitive function.

Gender

ALL

Eligibility criteria

• Key inclusion criteria:
• • (1)ischemic stroke, with an initial incident occurring within 2 weeks;(2)MoCA\<26;
• Key exclusion criteria:
• • (1)Cerebral hemorrhage or subarachnoid hemorrhage;(2)A pre-existing history of epilepsy;